Vitamin K2 (menaquinone-7) prevents age-related deterioration of trabecular bone microarchitecture at the tibia in postmenopausal women.
OBJECTIVE
Clinical studies suggest that vitamin K2 protects against bone loss and fractures; however, its effect on bone quality has never been investigated. We investigated the effect of vitamin MK-7 on undercarboxylated osteocalcin (ucOC), and bone mass and quality.


METHODS
We conducted a randomised, placebo-controlled, double-blinded clinical trial.


METHODS
We investigated the effect of MK-7 375 µg for 12 months on bone mineral density (BMD) measured by dual X-ray absorptiometry (DXA), bone microarchitecture measured by high-resolution peripheral quantitative computed tomography (HRpQCT) and biochemical bone turnover markers in 148 postmenopausal women with osteopenia. All of them were supplemented with calcium and vitamin D.


RESULTS
ucOC decreased in the MK-7 group (-65.6 (59.1; 71.0) %) (median (CI)) compared with the placebo group (-6.4 (-13.5; 1.2) %) after 3 months (P < 0.01). HRpQCT after 12 months demonstrated that trabecular number in tibia was unchanged in the MK-7-group (-0.1 ± 1.9%) (mean ± s.d.) and decreased in the placebo group (-3.5 ± 2.2%), trabecular spacing was unchanged in the MK-7 group (+1.2 ± 8.0%) and increased in the placebo group (+4.5 ± 9.7%), and trabecular thickness was unchanged in the MK-7 group (+0.2 ± 1.7%) and increased in the placebo group (+4.0 ± 2.2%) (between-group changes for all: P < 0.05). There were no significant differences between the groups in HRpQCT-derived parameters at the radius or in BMD at any site.


CONCLUSIONS
The changes in bone microarchitecture in the placebo group are consistent with the age-related deterioration of trabecular structure, with a loss of trabeculae and a greater mean thickness of the remaining trabeculae. This suggests that vitamin MK-7 preserves trabecular bone structure at the tibia.
Department of Endocrinology and Internal MedicineAarhus University Hospital, Aarhus C, Denmark sofie.roenn@auh.rm.dk.
Sofie Hertz
SH
Rønn
Department of Endocrinology and Internal MedicineAarhus University Hospital, Aarhus C, Denmark.
Torben
T
Harsløf
Department of Endocrinology and Internal MedicineAarhus University Hospital, Aarhus C, Denmark.
Steen Bønløkke
SB
Pedersen
Department of Endocrinology and Internal MedicineAarhus University Hospital, Aarhus C, Denmark.
Bente Lomholt
BL
Langdahl
D015502:Absorptiometry, Photon; D000367:Age Factors; D000368:Aged; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001851:Bone Diseases, Metabolic / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000378:metabolism; D000071556:Cancellous Bone / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000378:metabolism; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000000981:diagnostic imaging / Q000378:metabolism / Q000517:prevention & control; D017698:Postmenopause / Q000187:drug effects / Q000378:metabolism; D013977:Tibia / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000378:metabolism; D014057:Tomography, X-Ray Computed; D024482:Vitamin K 2 / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D024482:Vitamin K 2